• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Leidos, NIH Launches Portal to Re-accelerate Biomedical Research Funding

by Fred Pennic 03/24/2016 Leave a Comment

 

OnPAR

Leidos, a health, national security and engineering solutions company is teaming up with the National Institutes of Health (NIH) to launch OnPAR (Online Partnership to Accelerate Research) that will provide new funding opportunities for scientific projects. The Online Partnership to Accelerate Research (OnPAR) was conceived to re-accelerate the biomedical research and development enterprise by seeking a larger return on NIH’s peer review investment on research proposals evaluated in the top 30% in each NIH Institute and Center. Leidos has developed the OnPAR processes and website and will manage the overall program.

There is currently a surplus of high-quality biomedical research applications that merit funding through alternative sources. The goal of OnPAR is to match quality biomedical research projects with priority areas of interest of private foundations, and pharmaceutical and biotech companies and/or other private biomedical research funders. OnPAR will eventually provide access to a global pipeline of research projects that can either supplement internal projects or provide innovative new ideas for future medical products.

“OnPAR presents another avenue to fund important biomedical research,” said Jim Pannucci, Leidos Director, Life Sciences.  “The program will revolutionize the scientific funding environment and foster more discoveries at a faster pace to benefit and improve global health.”

Research projects will be considered and funded by OnPAR funding organization members based on their specific research priority areas and requirements. For the pilot project, funding organization members include the Adenoid Cystic Carcinoma Research Foundation, the Breast Cancer Research Foundation, theChildren’s Tumor Foundation, the JDRF, the Melanoma Research Alliance, the National Alopecia Areata Foundation, and the Parent Project Muscular Distropy.  These foundations were selected to span different disease areas and varied foundation sizes.

As the program progresses, OnPAR is planning on increasing its membership to include additional foundations, pharmaceutical companies, and other life sciences funding organizations across varied disease areas. In addition, Leidos foresees expanding the program globally to present an alternative option to the traditional government grant mechanisms.

Tagged With: Leidos, NIH, OnPAR

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |